



NEWS RELEASE

For Further Information Contact:

Paul Averback
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com

For Immediate Release:

Nymox Announces Appointment of James G. Robinson to Board of Directors

HASBROUCK HEIGHTS, NJ (July 30, 2015) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that the Company has newly appointed James G. Robinson to the Board of Directors.

Mr. Robinson is a prominent and highly successful entrepreneur whose career spans multiple decades in the automotive and film industries with vast business experience in the areas of conception, management, operations, distribution and marketing in both the U.S. and global markets.

For the past 28 years through Mr. Robinson's initiative and astute leadership as Chairman and CEO, Morgan Creek has continued to prosper as one of the foremost independent film production companies. Morgan Creek has produced an assortment of highly successful and critically acclaimed features including the Young Guns, Major League and Ace Ventura franchises, the award winning Enemies, A Love Story; and the blockbuster Robin Hood: Prince of Thieves. Later this year, production will begin on the highly anticipated Tupac, the story of the rapper, actor and activist Tupac Shakur.

Dr. Paul Averback, CEO and Chairman of Nymox said, "We are delighted to welcome Jim to the Board of Nymox, where he will be a valuable member who will bring hugely successful experience and imagination to our Company. Jim has been a long-term supporter of the Company in the past and this is great news for our shareholders."

For more information please contact info@nymox.com or 800-936-9669.

The July 27th webcast of news and discussion by experts of the Company's new clinical trial results can be viewed at http://limelightdc.com/clientarea/nymox_investor_webcast_7_15/player_vod.html. The link is also available at the Company's website.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Development of drug products involves substantial risks and actual results may differ materially from expectations. Factors that could cause actual results or events to differ materially from those projected in forward-looking statements are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

###